Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF1090 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TWEAK/TNFSF12 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human TWEAK in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) BAFF, rhFas Ligand, rhGITR Ligand, rhOX40 Ligand, rhTRAIL and less than 1% cross-reactivity with rhAPRIL, rhLIGHT, rhTNF-alpha , rhVEGI, and rhTRANCE is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q4ACW9- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.
Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins.
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Stephan D, Sbai O, Wen J, Couraud PO, Putterman C, Khrestchatisky M, Desplat-Jégo S
Journal of neuroinflammation 2013 Jan 15;10:9
Journal of neuroinflammation 2013 Jan 15;10:9
Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins.
Inoue T, Tashiro Y, Takeuchi M, Otani T, Tsuji-Takayama K, Okochi A, Mukae Y, Koreishi M, Yamasaki F, Kumon H, Nakamura S, Kibata M, Kondo E
International journal of oncology 2011 May;38(5):1299-306
International journal of oncology 2011 May;38(5):1299-306
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O
Arteriosclerosis, thrombosis, and vascular biology 2010 Jun;30(6):1253-62
Arteriosclerosis, thrombosis, and vascular biology 2010 Jun;30(6):1253-62
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TWEAK/TNFSF12 in MDA-MB-231 Human Cell Line. TWEAK/TNFSF12 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using 10 µg/mL Goat Anti-Human TWEAK/TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TWEAK/TNFSF12 Inhibition of Cell Proliferation and Neutralization by Human TWEAK/TNFSF12 Antibody. Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW) inhibits proliferation in the the HT-29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line). Activity elicited by Recombinant Human TWEAK/TNFSF12 (1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TWEAK/ TNFSF12 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1090). The ND50 is typically 2-8 µg/mL.
